Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1113-1119

  Xu, L ^a   Pozniak, A ^b   Wildfire, A ^b   Stanfield Oakley, S A ^d   Mosier, S M ^d   Ratcliffe, D ^a   Workman, J ^a   Joall, A ^a   Myers, R ^c   Smit, E ^a   Cane, P A ^a   Greenberg, M L ^d   Pillay, D ^a,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Trimeris Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; ANTIRETROVIRUS AGENT; ENFUVIRTIDE; GLUTAMINE; GLYCOPROTEIN GP 41; HISTIDINE; SERINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; GENETIC POLYMORPHISM; HEPTAD REPEAT 1; HEPTAD REPEAT 2; HUMAN; HUMAN CELL; LONG TERM CARE; MOLECULAR EVOLUTION; MOLECULAR MODEL; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; REBOUND; REPORTER GENE; TREATMENT FAILURE; VIROLOGY;

AMINO ACID SEQUENCE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; REPETITIVE SEQUENCES, AMINO ACID;

EID: 20044371998     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1113-1119.2005     Document Type: Article

References (38)

1. Cao, J., L. Bergeron, E. Helseth, M. Thali, H. Repke, and J. Sodroski. 1993. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67:2747-2755.
2. Chambers, P., C. R. Pringle, and A. J. Easton. 1990. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 71(Pt 12):3075-3080.
3. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
4. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
5. Chen, C. H., T. J. Matthews, C. B. McDanal, D. P. Bolognesi, and M. L. Greenberg. 1995. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J. Virol. 69:3771-3777.
6. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, Z. Zhang, W. A. O'Brien, L. Ratner, G. M. Shaw, and E. Hunter. 2001. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75:8605-8614.
7. Dorn, J., S. Masciotra, C. Yang, R. Downing, B. Biryahwaho, T. D. Mastro, J. Nkengasong, D. Pieniazek, M. A. Rayfield, D. J. Hu, and R. B. Lal. 2000. Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection. J. Clin. Microbiol. 38:773-780.
8. Gallaher, W. R., J. M. Ball, R. F. Garry, M. C. Griffin, and R. C. Montelaro. 1989. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retrovir. 5:431-440.
9. Greenberg, M. L., T. Melby, P. Sista, R. DeMasi, N. Cammack, M. Salgo, et al. 2003. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks, abstr. 141. 10th Conf. Retrovir. Opportun. Infect., 2003.
10. Hanna, S. L., C. Yang, S. M. Owen, and R. B. Lai. 2002. Resistance mutation in HIV entry inhibitors. AIDS 16:1603-1608.
11. Helseth, E., U. Olshevsky, C. Furman, and J. Sodroski. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65:2119-2123.
12. Hu, Q., J. O. Trent, G. D. Tomaras, Z. Wang, J. L. Murray, S. M. Conolly, J. M. Navenot, A. P. Barry, M. L. Greenberg, and S. C. Peiper. 2000. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J. Mol. Biol. 302:359-375.
13. Hu, Q. X., A. P. Barry, Z. X. Wang, S. M. Connolly, S. C. Peiper, and M. L. Greenberg. 2000. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 74:11858-11872.
14. Jiang, S., K. Lin, N. Strick, and A. R. Neurath. 1993. HIV-1 inhibition by a peptide. Nature 365:113.
15. Jones, S., and J. M. Thornton. 1996. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. USA 93:13-20.
16. Kemp, S. D., L. Ruiz, A. M. Lucas, A. Bonjoch, J. Martinez-Picado, B. A. Larder, et al. 2002. Novel mutations in a highly conserved region of HIV-1 gp41 are associated with T-20 treatment. Antivir. Ther. 7:S11.
17. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
18. Kilby, J. M., J. P. Lalezari, J. J. Eron, M. Carlson, C. Cohen, R. C. Arduino, J. C. Goodgame, J. E. Gallant, P. Volberding, R. L. Murphy, F. Valentine, M. S. Saag, E. L. Nelson, P. R. Sista, and A. Dusek. 2002. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retrovir. 18:685-693.
19. Lalezari, J. P., K. Henry, M. O'Hearn, J. S. Montaner, P. J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. R. Kuritzkes, J. J. Eron, Jr., J. Chung, R. DeMasi, L. Donatacci, C. Drobnes, J. Delehanty, M. Salgo, and the TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
20. Lazzarin, A., B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H. J. Stellbrink, J. F. Delfraissy, J. Lange, L. Huson, R. DeMasi, C. Wat, J. Delehanty, C. Drobnes, M. Salgo, and TORO 2 Study Group. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2186-2195.
21. Louis, J. M., C. A. Bewley, and G. M. Clore. 2001. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. 276:29485-29489.
22. McLachlan, A. D., and M. Stewart. 1975. Tropomyosin coiled-coil interactions: evidence for an unstaggered structure. J. Mol. Biol. 98:293-304.
23. Poveda, E., B. Rodes, C. Toro, L. Martin-Carbonero, J. Gonzalez-Lahoz, and V. Soriano. 2002. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 27:1959-1961.
24. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993.
25. Roman, F., D. Gonzalez, C. Lambert, S. Deroo, A. Fischer, T. Baurith, T. Staub, R. Boulme, V. Arendt, F. Schneider, R. Hemmer, and J. C. Schmit. 2003. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J. Acquir. Immune Defic. Syndr. 33:134-139.
26. Root, M. J., M. S. Kay, and P. S. Kim. 2001. Protein design of an HIV-1 entry inhibitor. Science 291:884-888.
27. Sista, P., T. Melby, M. L. Greenberg, D. Davison, L. Jin, S. Mosier, et al. 2002. Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. Antivir. Ther. 7:S16.
28. Sista, P. R., T. Melby, D. Davison, L. Jin, S. Mosier, M. Mink, E. L. Nelson, R. DeMasi, N. Cammack, M. P. Salgo, T. J. Matthews, and M. L. Greenberg. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18:1787-1794.
29. Trottier, B., K. Arasteh, K. Henry, C. Katlama, A. Lazzarin, J. Montaner, et al. 2003. Durability of response of enfuvirtide through 48 weeks in the TORO trials, abstr. H-835. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
30. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
31. Weissenhorn, W., A. Dessen, L. J. Calder, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1999. Structural basis for membrane fusion by enveloped viruses. Mol. Membr. Biol. 16:3-9.
32. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430.
33. Wild, C., T. Greenwell, and T. Matthews. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retrovir. 9:1051-1053.
34. Wild, C., T. Greenwell, D. Shugars, L. Rimsky-Clarke, and T. Matthews. 1995. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retrovir. 11:323-325.
35. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
36. Xu, L., S. Hue, S. Taylor, D. Ratcliffe, J. A. Workman, S. Jackson, P. A. Cane, and D. Pillay. 2002. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 16:1684-1686.
37. Young, L., R. L. Jernigan, and D. G. Covell. 1994. A role for surface hydrophobicity in protein-protein recognition. Protein Sci. 3:717-729.
38. Zollner, B., H. H. Feucht, M. Schroter, P. Schafer, A. Plettenberg, A. Stoehr, and R. Laufs. 2001. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 15:935-936.